相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus
Harold E. Bays et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia
Tadashi Yamakawa et al.
ENDOCRINE JOURNAL (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes
Franklin J. Zieve et al.
CLINICAL THERAPEUTICS (2007)
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
Emanuele Bosi et al.
DIABETES CARE (2007)
Bile acid sequestrants and the treatment of type 2 diabetes mellitus
Bart Staels et al.
DRUGS (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes
M. A. Nauck et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2006)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia
Isabel Matias et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Investigational treatments for Type 2 diabetes mellitus:: exenatide and liraglutide
Claudio Gonzalez et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes
James Mu et al.
DIABETES (2006)
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
R. E. Pratley et al.
HORMONE AND METABOLIC RESEARCH (2006)
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review
William Insull
SOUTHERN MEDICAL JOURNAL (2006)
Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways
BN Friedrichsen et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes
MN Feinglos et al.
DIABETIC MEDICINE (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Glucagon-like peptide 1(GLP-1) in biology and pathology
JJ Meier et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
SH Saydah et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
E Selvin et al.
ANNALS OF INTERNAL MEDICINE (2004)
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
H Harder et al.
DIABETES CARE (2004)
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
B Ahrén et al.
DIABETES CARE (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) A 12-week, double-blind, randomized, controlled trial
S Madsbad et al.
DIABETES CARE (2004)
Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by mass during the prediabetic expansion of the β-cell period with glucagon-like peptide-1 or exendin-4
C Tourrel et al.
DIABETES (2002)
Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age
C Tourrel et al.
DIABETES (2001)
分享论文
